MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

148.10
+1.51
+1.03%
After Hours: 148.11 +0.01 +0.01% 16:31 02/26 EST
OPEN
147.01
PREV CLOSE
146.59
HIGH
149.00
LOW
143.91
VOLUME
504.67K
TURNOVER
--
52 WEEK HIGH
178.41
52 WEEK LOW
84.97
MARKET CAP
17.33B
P/E (TTM)
-19.8683
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Steven Cohen Dives Into Chimerix
GuruFocus News · 2d ago
EVER, FIVN, CLMT and API among after-hours movers
Gainers: [[EVER]] +12.3%. [[ZI]] +11.3%. [[FIVN]] +9.3%. [[FREQ]] +8.3%. [[VBLT]] +7.6%.Losers: [[CLMT]] -14.7%. [[XELB]] -10.9%. [[API]] -9.8%. [[ALNY]] -7.9%. [[REAL]] -5.7%.
Seekingalpha · 3d ago
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the...
BusinessWire - BZX · 4d ago
Delta Air, Foot Locker, Nvidia, Petrobras and More Monday Afternoon Analyst Calls
247WallSt.com · 4d ago
DJ Alnylam Pharmaceuticals Price Target Announced at $162.00/Share by Guggenheim
Dow Jones · 4d ago
DJ Alnylam Pharmaceuticals Cut to Neutral From Buy by Guggenheim
Dow Jones · 4d ago
--Analyst Actions: Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral From Buy; Price Target is $162
MT Newswires · 4d ago
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 11:20 am ET.
Business Wire · 02/18 21:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALNY. Analyze the recent business situations of Alnylam Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALNY stock price target is 174.09 with a high estimate of 235.00 and a low estimate of 88.00.
EPS
Institutional Holdings
Institutions: 554
Institutional Holdings: 114.49M
% Owned: 97.86%
Shares Outstanding: 117.00M
TypeInstitutionsShares
Increased
125
2.79M
New
88
657.98K
Decreased
116
3.76M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.83%
Key Executives
Chairman/Director
Michael Bonney
President/Chief Operating Officer
Yvonne Greenstreet
Chief Executive Officer/Director
John Maraganore
Chief Financial Officer/Executive Vice President
Jeffrey Poulton
Corporate Executive
Akshay Vaishnaw
Chief Human Resource Officer/Senior Vice President
Kelley Boucher
Executive Vice President/Secretary
Laurie Keating
Senior Vice President/Chief Scientific Officer
Kevin Fitzgerald
Senior Vice President
Salil Patel
Other
Agnieszka Gallagher
Other
Tolga Tanguler
Director
Olivier Brandicourt
Independent Director
Dennis Ausiello
Independent Director
Marsha Fanucci
Independent Director
Margaret Hamburg
Independent Director
Steven Paul
Independent Director
David Pyott
Independent Director
Colleen Reitan
Independent Director
Amy Schulman
Independent Director
Phillip Sharp
  • Dividends
  • Splits
  • Insider Activity
No Data
About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.